Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

NCT04159519 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04159519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04159519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
July 27, 2020
Completion date
January 31, 2023
Enrollment
170 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, severe eosinophilic asthma